AdAlta Secures A$1.2m Placement to Accelerate ‘East to West’ CAR-T Strategy

AdAlta Ltd. ( (AU:1AD) ) has issued an announcement.

AdAlta has secured binding commitments from a restricted group of sophisticated and high-net-worth investors to raise A$1.2 million via a private placement priced at A$0.005 per share, accompanied by attaching options exercisable at A$0.01 and expiring in June 2028. The capital, raised at a premium to its previous placement and supported by strong demand following its recent CAR-T collaboration with Shanghai Cell Therapy Group, is intended to strengthen the company’s balance sheet, bolster negotiations for third-party financing of its AdCella subsidiary, advance development of its licensed PD1-armored MSLN CAR-T candidate BZDS1901 for advanced mesothelioma, and support further licensing and pipeline expansion under its ‘East to West’ cellular immunotherapy strategy.

The most recent analyst rating on (AU:1AD) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on AdAlta Ltd. stock, see the AU:1AD Stock Forecast page.

More about AdAlta Ltd.

AdAlta Limited is an ASX-listed, clinical-stage biotechnology company focused on developing next-generation cellular immunotherapies for solid cancers. Through its ‘East to West’ strategy, it in-licenses highly differentiated T cell therapy assets from Asian, particularly Chinese, innovators and advances them through FDA-regulated manufacturing and early-phase clinical trials in Australia, with the aim of later partnering with larger biopharmaceutical companies. The company also has a first-in-class fusion protein, AD-214, targeting fibrotic lung and kidney diseases such as idiopathic pulmonary fibrosis, which has completed Phase I studies and is available for partnering.

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$13.77M

Find detailed analytics on 1AD stock on TipRanks’ Stock Analysis page.